Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bern Daily Press.
Press releases published on August 28, 2025

ORIGYN Surpasses $51.3M in Certified Real-World Assets On-Chain
ORIGYN’s TVL has reached another milestone of $51.3 million, a powerful signal of growing trust, adoption, and validation of certified RWA on-chain. NEUCHâTEL, SWITZERLAND, August 28, 2025 /EINPresswire.com/ -- ORIGYN, the protocol dedicated to …

Le Dictionnaire Idéal s’impose comme la nouvelle référence éducative : déjà adopté dans 40 pays depuis son lancement
Un dictionnaire conçu pour les besoins concrets des élèves, mais aussi des adultes d’aujourd’hui, à la portée internationale avec 20 langues disponibles. PARIS, FRANCE, August 28, 2025 /EINPresswire.com/ -- Lancé il y a à peine deux mois, et disponible …

SECO annuncia Clea OS 2.0
Supporto a lungo termine e cybersecurity avanzata per la prossima generazione di dispositivi smart AREZZO, ITALY, August 28, 2025 /EINPresswire.com/ -- SECO S.p.A. (“SECO” o la “Società”) lancia Clea OS v.2.0, un’importante evoluzione del proprio …

WISeKey’s WISeSat Subsidiary Expand its Ground Segment Network in Switzerland
WISeKey’s WISeSat Subsidiary Expand its Ground Segment Network in Switzerland Lausanne, Switzerland – August 28, 2025 - WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, …

OG of fast cars drops in games: Porsche adopts in-car gaming with AirConsole
Zurich, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AirConsole, the pioneering in-car gaming platform that transforms car rides into shared entertainment experiences, is arriving in the new Porsche Macan later this year. This collaboration will bring a curated …

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC) 1 in 5 cancer-related deaths in the US are …

Oculis to Participate in Upcoming September Investor Conferences
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet …

Ascom and AvaSure partner in AI-powered virtual nursing solutions for North America
Baar, Switzerland, August 28, 2025 Ascom, a leading provider of clinical workflow and mobile communication solutions, and AvaSure, a leader in AI-powered virtual care, have signed a multi-year Interoperability Partner Agreement to integrate AvaSure’s …

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for …